Navigation Links
Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that data from preclinical studies of INNO-406, a potent oral dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to the presentations is as follows: -0-

Presentation Title:    "The dual ABL/SRC inhibitors dasatinib,

                       SKI-606, and INNO-406 are potent inhibitors of

                       T cell acute lymphoblastic leukemia cell lines

                       expressing the NUP214-ABL1 fusion kinase"


Abstract Number:       1825


Session:               Poster Section 7, Clinical Research 8, Poster

                       Board #11


Session Date and Time: Monday, April 16, 2007, 8:00 a.m. - 12:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center





Presentation Title:    "Cell death and autophagy induced by INNO-406,

                       a novel Bcr-Abl inhibitor, in Philadelphia

                       leukemias"


Abstract Number:       2768


Session:               Poster Section 10, Cellular and Molecular

                       Biology 31, Poster Board #17


Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center

-0-
Presentation Title:    "Overcoming imatinib resistance using Src

                       inhibitor CGP76030, Abl inhibitor nilotinib,

                       and Abl/Lyn inhibitor INNO-406 in newly

                       established K562 variants with bcr-abl gene

                       amplification"


Abstract Number:       3246


Session:               Poster Section 29, Experimental and Molecular

                     
  Therapeutics 26, Poster Board #8


Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center

About INNO-406

INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.

Contact

INNOVIVE Pharmaceuticals
Steve Kelly
President and CEO
212-716-1820
or
Porter Novelli Life Sciences
Rachel Lipsitz
Media & Investor Relations
619-849-5378


'"/>




Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
Breaking Medicine Technology:
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... ... LLC and expands services in Northern Colorado. Aspire Autism, A Division of Autism ... Applied Behavior Analysis (ABA) services. Aspire provides center based Autism services in Broomfield ...
(Date:9/26/2017)... ... September 26, 2017 , ... DETECTO ... Effective October 1, 2017, the new agreement allows Premier members, at their discretion, ... scales. , “DETECTO is pleased to renew our agreement with Premier to be ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... “How to Live in the Millennium”: ... Satan and his minions are no longer a part of everyday life and do not ... we are and take responsibility for the thoughts, words, and actions that are chosen. ...
(Date:9/26/2017)... ... ... Ballad of Cowboy Justin”: a charming tale of a brave cowboy who saves the ... published author, Leah Westbrook, a wife and mother who loves to spend time with ... tale about a young brave cowboy, Cowboy Justin, who saves the town from a ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: an ... help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is the ... Navy for nine years. He received his BS from Idaho State University in ...
Breaking Medicine News(10 mins):